Blog
RSS FeedPosted by Michael Wonder on 18 Feb 2019
Hospital drug prices are up to 7 times greater than Medicare pricing
15 February 2019 - A new study shows something many healthcare patients know all too well: hospitals are charging significant ...
Posted by Michael Wonder on 08 Feb 2019
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...
Posted by Michael Wonder on 06 Feb 2019
Comparing PHARMAC's outcomes with those of Australia
7 February 2019 - New Zealand's Prime Minister Jacinda Ahern's claim that is unfair to compare PHARMAC's outcomes with those ...
Posted by Michael Wonder on 05 Feb 2019
Jacinda Ardern: not fair to compare PHARMAC with Australia's system
5 February 2019 - Jacinda Ardern told The AM Show New Zealand's drug buying agency has "been pointed to as being ...
Posted by Michael Wonder on 20 Jan 2019
The U.S. should assess the economic value of drugs rather than leave it up to other countries
17 January 2019 - One reason why prescription drugs are often priced lower overseas is that many countries perform detailed ...
Posted by Michael Wonder on 19 Dec 2018
Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score
19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...
Posted by Michael Wonder on 11 Dec 2018
Dozens of groups attack Trump plan to peg drug prices to what other countries pay
10 December 2018 - A controversial Trump administration plan to lower drug costs by pegging prices to what are paid ...
Posted by Michael Wonder on 05 Dec 2018
International price index for medicine will harm patients
4 December 2018 - President Trump was elected on his promise to stop other nations from taking advantage of the ...
Posted by Michael Wonder on 19 Nov 2018
The bizarre world of drug pricing
19 November 2018 - There is no shortage of bad ideas when it comes to the pharmaceutical market. One such ...
Posted by Michael Wonder on 12 Nov 2018
PBAC shows no propensity to support Amgen's innovative method of analysis
12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...
Posted by Michael Wonder on 30 Oct 2018
Comparison of U.S. and international prices for top Medicare Part B drugs by total expenditures
25 October 2018 - The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as ex- manufacturers prices) ...
Posted by Michael Wonder on 09 Oct 2018
Outdated public funding model failing New Zealand patients
9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...
Posted by Michael Wonder on 25 Aug 2018
This drug is safe and effective. Wait. Compared with what?
20 August 2018 - Comparative effectiveness research may be the best way to answer questions that patients and physicians face every ...
Posted by Michael Wonder on 21 Aug 2018
FDA analysis shows similar success rates for paediatric trials using clinical and surrogate outcomes
21 August 2018 - An analysis by US FDA officials published earlier this month finds that there is a similar ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...